Hey-Song Corp. AI Stock Analysis
Hey-Song Corp. (1234) AI Stock Analysis
Hey-Song Corp.
(TWSE:1234)
Hey-Song scores in the lower-middle range, held back primarily by a sharp deterioration in cash generation — operating cash flow has collapsed to NT$244m and free cash flow turned negative for the first time — alongside two consecutive years of revenue decline and a dramatic compression in operating and EBITDA margins. Offsetting this is an exceptionally conservative balance sheet with debt-to-equity of only 0.11 and ~79% equity funding, plus stable ~28% gross margins, which give the company ample room to absorb a soft patch. Technicals reinforce caution, with the price trading below all major moving averages and negative MACD momentum. A 5.16% dividend yield and very low beta offer defensive appeal, but a 19.5x P/E looks full given weak returns on equity and earnings increasingly reliant on non-operating income. Investors should look for stabilisation in operating profitability and cash conversion before the risk/reward improves.
Hey-Song Corp. (1234) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 12.82B
- Dividend Yield
- 5.17%
- Average Volume (3M)
- 98.18K
- Price to Earnings (P/E)
- 19.5
- Beta (1Y)
- 0.08
- Revenue Growth
- -7.77%
- EPS Growth
- -27.50%
- Country
- TW
- Employees
- 20,419
- Sector
- General
- Sector Strength
- 55
- Industry
- Beverages - Non-Alcoholic
Hey-Song Corp. Business Overview & Revenue Model
Company Description
Hey Song Corporation manufactures and sells beverages and alcoholic beverages under its own brands, provides OEM and sales services for other well-known brands in Taiwan. The company offers carbonated drinks under the HeySong Sarsaparilla, C&C, and H...
Hey-Song Corp. Financial Statement Overview
Summary
A tale of two halves. The balance sheet is a genuine fortress (score 80): equity funds ~79% of assets, debt-to-equity is just 0.11, and equity has compounded steadily since 2020, leaving minimal solvency risk. The income statement (score 54) is mixed — gross margin is impressively stable near 28%, but revenue has declined two years running to NT$9.51bn and operating profit collapsed from NT$694m to NT$416m, with EBITDA margin halving to 6.3%. Net income exceeding operating profit signals a lower-quality earnings mix reliant on non-operating income. Cash flow is the clear weak spot (score 33): operating cash flow has fallen every year to just NT$244m, free cash flow turned negative at NT$132m, and cash conversion dropped to roughly 0.3x net income. ROE of ~4%-5% underscores poor capital efficiency on a large asset base.
Income Statement
54NeutralBalance Sheet
80PositiveCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.25B | 9.51B | 10.25B | 10.58B | 9.56B | 9.22B |
| Gross Profit | 2.66B | 2.66B | 3.05B | 2.97B | 2.68B | 2.56B |
| EBITDA | 1.01B | 595.97M | 1.56B | 1.53B | 1.46B | 1.37B |
| Net Income | 658.83M | 804.35M | 947.40M | 948.45M | 886.13M | 796.81M |
Balance Sheet | ||||||
| Total Assets | 24.36B | 23.93B | 23.69B | 22.76B | 22.76B | 22.79B |
| Cash, Cash Equivalents and Short-Term Investments | 1.72B | 1.52B | 1.59B | 1.61B | 1.50B | 1.51B |
| Total Debt | 1.94B | 2.04B | 1.63B | 773.44M | 1.04B | 1.22B |
| Total Liabilities | 5.92B | 5.08B | 4.85B | 4.11B | 4.41B | 4.64B |
| Stockholders Equity | 18.44B | 18.85B | 18.83B | 18.65B | 18.35B | 18.14B |
Cash Flow | ||||||
| Free Cash Flow | 265.06M | -131.85M | 64.41M | 1.03B | 592.25M | 872.08M |
| Operating Cash Flow | 559.15M | 244.19M | 772.27M | 1.29B | 813.24M | 1.10B |
| Investing Cash Flow | -443.57M | -8.29M | -981.86M | 185.47M | -218.20M | -650.51M |
| Financing Cash Flow | -187.39M | -383.75M | 64.69M | -993.28M | -852.87M | -494.63M |
Hey-Song Corp. Peers Comparison
Overall Rating
TW:170773Outperform
TW:321873Outperform
TW:275372Outperform
TW:846268Neutral
TW:843662Neutral
TW:123454Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | TWD 11.75B | 10.96 | ― | 7.62% | -5.38% | -12.85% | |
| 73Outperform | TWD 10.68B | 9.40 | ― | 6.15% | 0.24% | 28.93% | |
| 72Outperform | TWD 12.39B | 12.75 | ― | 6.19% | 7.94% | 16.15% | |
| 68Neutral | TWD 12.09B | 12.67 | ― | 4.97% | 19.42% | 56.90% | |
| 62Neutral | TWD 10.68B | 10.48 | ― | 6.58% | -3.82% | 2.23% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | TWD 12.84B | 19.45 | ― | 5.17% | -7.77% | -27.50% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1234 | Hey-Song Corp. | 31.90 | -3.64 | -10.24% | |
| TW:1707 | Grape King Bio Ltd. | 78.70 | -43.39 | -35.54% | |
| TW:2753 | Bafang Yunji International Co., Ltd. | 177.00 | -3.53 | -1.95% | |
| TW:3218 | Universal Vision Biotechnology Co., Ltd. | 126.00 | -20.80 | -14.17% | |
| TW:8436 | TCI Co., Ltd. | 91.40 | -24.30 | -21.00% | |
| TW:8462 | Power Wind Health Industry Incorporated | 146.50 | -1.64 | -1.11% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
